With FDA-approved indications for both chronic lymphocytic leukemia and acute myeloid leukemia, and continued investigation within multiple disease states, venetoclax has become an exciting oral targeted therapy among oncologists.
While ibrutinib plus rituximab may improve progression-free survival in chronic lymphocytic leukemia, it is a costly option for some patients.
The CLARITY trial looked at measurable residual disease negativity in 54 patients with relapsed or refractory chronic lymphocytic leukemia who received ibrutinib in combination with venetoclax.
Five-year follow-up of the phase III COMPLEMENT 1 study focused on the efficacy with respect to overall and progression-free survival.
The combination of ibrutinib and nivolumab showed promising clinical response in patients with Richter’s Transformation.
A patient’s minimal residual disease status may serve as a surrogate marker for outcome in clinical trials of chronic lymphocytic leukemia in patients with comorbidities.
Testing patterns associated with the diagnosis and treatment of chronic lymphocytic leukemia have changed rapidly during the last decade.
Researchers analyzed a new recurrent BCL2 mutation appearing in a cohort of patients with CLL-type progressions treated with venetoclax.
Leukemia cells show sensitivity to restriction of BCL2 and BTK with the combination of venetoclax and ibrutinib.
Long-term data from the phase III HELIOS trial indicates ibrutinib plus bendamustine and rituximab improve survival outcomes in CLL patients.